Genetic Technologies' Phenogen Sciences Inc. subsidiary launched BREVAGenplus in the U.S. to assess a women's risk of developing sporadic or non-hereditary breast cancer. According to Genetic Technologies, the test is designed for Caucasian, Hispanic and...

Genetic Technologies' Phenogen Sciences Inc. subsidiary launched the BREVAGen genetic test in the U.S. to determine a patient's lifetime and five-year risk for developing non-familial breast cancer. The breast cancer stratification test combines a DNA-based...